ANIK Anika Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 898437 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY52.5%
TTM net income YoY94.7%
TTM EPS YoY94.3%
Revenue 3-yr CAGR-8.9%
Net income 3-yr CAGR—
Margins
Gross margin63.4%
Operating margin-2.1%
Net margin-1.4%
FCF margin1.9%
EBITDA margin2.5%
Returns
ROE-1.2%
ROA-0.9%
ROIC (approx.)-2.3%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets27.4%
Debt / equity0.00x
Current ratio3.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.24x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $112.82M | $119.91M | $120.79M | $113.83M | $147.79M |
| Cost of revenue | $49.01M | $43.91M | $38.26M | $40.61M | $64.85M |
| Gross profit | $63.81M | $76.00M | $82.53M | $73.22M | $82.94M |
| R&D expense | $25.77M | $25.54M | $21.76M | $18.32M | $27.33M |
| SG&A expense | $49.09M | $55.55M | $59.92M | $51.23M | $74.10M |
| Operating income | -$11.05M | -$5.10M | $844,000 | $3.67M | $2.62M |
| Pretax income | -$9.31M | -$2.76M | $3.16M | $4.32M | $2.43M |
| Income tax | $672,000 | $6.06M | $6.59M | $2.12M | -$1.71M |
| Net income | -$10.88M | -$56.38M | -$82.67M | -$14.86M | $4.13M |
| EBITDA | -$5.68M | $1.78M | $7.28M | $10.37M | $9.10M |
| EPS (basic) | -0.76 | -3.83 | -5.64 | -1.02 | 0.29 |
| EPS (diluted) | -0.76 | -3.83 | -5.64 | -1.02 | 0.28 |
| Weighted avg. shares (diluted) | 14.34M | 14.72M | 14.66M | 14.79M | 14.63M |
| Balance sheet | |||||
| Cash & equivalents | $57.48M | $55.63M | $68.74M | $86.33M | $94.39M |
| Short-term investments | $23.69M | $23.59M | $26.36M | $34.63M | $29.84M |
| Receivables | $23.69M | $23.59M | $26.36M | $34.63M | $29.84M |
| Inventory | $18.79M | $23.81M | $24.43M | $39.77M | $36.01M |
| Current assets | $103.36M | $113.65M | $163.31M | $169.55M | $168.53M |
| PP&E, net | $40.32M | $38.99M | $37.45M | $48.28M | $47.60M |
| Goodwill | $8.05M | $7.12M | $7.57M | $7.34M | $7.78M |
| Intangibles | $1.65M | $2.49M | $2.58M | $74.60M | $82.38M |
| Total assets | $190.27M | $202.74M | $270.63M | $349.13M | $347.54M |
| Current liabilities | $21.91M | $23.31M | $31.06M | $27.91M | $29.80M |
| Total liabilities | $46.80M | $48.75M | $58.37M | $63.56M | $60.45M |
| Shareholders' equity | $143.47M | $153.99M | $212.26M | $285.56M | $287.08M |
| Shares outstanding | 13.89M | 14.42M | 14.66M | 14.62M | 14.44M |
| Cash flow statement | |||||
| Operating cash flow | $11.19M | $5.40M | -$1.79M | $4.41M | $8.40M |
| Capital expenditure | $6.83M | $7.73M | $5.43M | $7.49M | $5.14M |
| Free cash flow | $4.36M | -$2.33M | -$7.21M | -$3.08M | $3.25M |
| Investing cash flow | -$401,000 | -$8.33M | -$5.43M | -$7.49M | -$3.12M |
| Financing cash flow | -$10.55M | -$12.73M | -$6.32M | -$4.85M | -$6.78M |
| Depreciation & amortization | $5.37M | $6.88M | $6.43M | $6.70M | $6.48M |
| Stock-based compensation | $10.08M | $13.13M | $15.24M | $14.31M | $11.09M |
| Share buybacks | $9.48M | $10.91M | $5.00M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.